iRhythm closes $237.5M cash acquisition of VitalConnect, adding MCT and multi-vitals monitoring

iRhythm Holdings, Inc.

Purchase consideration was $237.5M in cash, subject to customary adjustments, plus up to 423,334 shares issued at closing, funded from iRhythm's balance sheet.
iRhythm also provided $10.0M of working capital funding to VitalConnect between signing and closing.
Transaction is expected to enhance iRhythm's revenue growth rate beginning in 2027 while preserving its previously communicated 15% adjusted EBITDA margin target for 2027.
VitalConnect adds mobile cardiac telemetry, up to 30-day patient monitoring, four-in-one functionality, live look-in and monitoring of up to 11 physiological parameters.
Updated 2026 guidance inclusive of VitalConnect will be given on iRhythm's Q3 earnings call November 5, 2026; CEO Quentin Blackford cited expansion into inpatient and hospital-to-home care.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.